Search Results - "Leiter, L"

Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials by Chiu, S, Sievenpiper, J L, de Souza, R J, Cozma, A I, Mirrahimi, A, Carleton, A J, Ha, V, Di Buono, M, Jenkins, A L, Leiter, L A, Wolever, T M S, Don-Wauchope, A C, Beyene, J, Kendall, C W C, Jenkins, D J A

“…Background/Objectives: In the absence of consistent clinical evidence, there are concerns that fructose contributes to non-alcoholic fatty liver disease…”
Get full text

A systematic review and meta-analysis of randomized trials of substituting soymilk for cow's milk and intermediate cardiometabolic outcomes: understanding the impact of dairy alternatives in the transition to plant-based diets on cardiometabolic health by Erlich, M N, Ghidanac, D, Blanco Mejia, S, Khan, T A, Chiavaroli, L, Zurbau, A, Ayoub-Charette, S, Almneni, A, Messina, M, Leiter, L A, Bazinet, R P, Jenkins, D J A, Kendall, C W C, Sievenpiper, J L

“…Dietary guidelines recommend a shift to plant-based diets. Fortified soymilk, a prototypical plant protein food used in the transition to plant-based diets,…”
Get full text

Effect of canagliflozin on liver function tests in patients with type 2 diabetes by Leiter, L.A, Forst, T, Polidori, D, Balis, D.A, Xie, J, Sha, S

“…Abstract Aims To report changes in liver function tests observed with canagliflozin, a sodium glucose co-transporter 2 inhibitor, across phase 3 studies in…”
Get full text

Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study by Leiter, L. A., Lundman, P., da Silva, P. M., Drexel, H., Jünger, C., Gitt, A. K.

“…Diabet. Med. 28, 1343–1351 (2011) Aim  To assess the prevalence of persistent lipid abnormalities in statin‐treated patients with diabetes with and without the…”
Get full text

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial by Masmiquel, L, Leiter, L A, Vidal, J, Bain, S, Petrie, J, Franek, E, Raz, I, Comlekci, A, Jacob, S, van Gaal, L, Baeres, F M M, Marso, S P, Eriksson, M

“…Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk. We used the…”
Get full text

Stimulation of Cholecystokinin-A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients by Jordan, J, Greenway, FL, Leiter, LA, Li, Z, Jacobson, P, Murphy, K, Hill, J, Kler, L, Aftring, RP

“…Cholecystokinin (CCK) decreases meal size through activation of CCK‐A receptors on vagal afferents. We tested the hypothesis that the selective CCK‐A agonist…”
Get full text

relation of low glycaemic index fruit consumption to glycaemic control and risk factors for coronary heart disease in type 2 diabetes by Jenkins, D. J. A, Srichaikul, K, Kendall, C. W. C, Sievenpiper, J. L, Abdulnour, S, Mirrahimi, A, Meneses, C, Nishi, S, He, X, Lee, S, So, Y. T, Esfahani, A, Mitchell, S, Parker, T. L, Vidgen, E, Josse, R. G, Leiter, L. A

“…Aims/hypothesis Sugar has been suggested to promote obesity, diabetes and coronary heart disease (CHD), yet fruit, despite containing sugars, may also have a…”
Get full text

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study) by Aroda, V. R., Bailey, T. S., Cariou, B., Kumar, S., Leiter, L. A., Raskin, P., Zacho, J., Andersen, T. H., Philis-Tsimikas, A.

“…Aim To evaluate the efficacy and safety of adding insulin degludec (IDeg) to treatment in patients with type 2 diabetes receiving liraglutide and metformin and…”
Get full text

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials by Leiter, L. A., Müller‐Wieland, D., Baccara‐Dinet, M. T., Letierce, A., Samuel, R., Cariou, B.

“…Aim To assess the lipid‐lowering efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in people with…”
Get full text

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials by Leiter, L. A., Tinahones, F. J., Karalis, D. G., Bujas‐Bobanovic, M., Letierce, A., Mandel, J., Samuel, R., Jones, P. H.

“…Aim To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status. Methods…”
Get full text

Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease by Leiter, L. A., Cefalu, W. T., de Bruin, T. W. A., Xu, J., Parikh, S., Johnsson, E., Gause-Nilsson, I.

“…Aim To evaluate the long‐term efficacy, safety and tolerability of dapagliflozin versus placebo added to usual care in patients with type 2 diabetes mellitus…”
Get full text

Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials by Tinahones, F.J., Laufs, U., Cariou, B., Louie, M.J., Yang, J., Thompson, D., Leiter, L.A.

“…Increased body mass index (BMI) contributes to cardiovascular risk and may influence efficacy of therapeutic antibodies. We investigated the effect of baseline…”
Get full text

Gastrointestinal safety across the albiglutide development programme by Leiter, L. A., Mallory, J. M., Wilson, T. H., Reinhardt, R. R.

“…Gastrointestinal (GI) adverse events (AEs) are the most frequently reported treatment‐related AEs associated with glucagon‐like peptide‐1 receptor agonists…”
Get full text

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial by Leiter, L. A., Teoh, H., Mosenzon, O., Cahn, A., Hirshberg, B., Stahre, C. A. M., Hoekstra, J. B. L., Alvarsson, M., Im, K., Scirica, B. M., Bhatt, D. L., Raz, I.

“…The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in Myocardial Infarction (TIMI) 53 trial…”
Get full text

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials by Davidson, J. A., Desouza, C., Fonseca, V., Frias, J. P., Van Gaal, L., Giorgino, F., Chao, J., Dex, T. A., Roberts, M., Saremi, A., Leiter, L. A.

“…Aims Both fasting (FPG) and postprandial plasma glucose (PPG) contribute to HbA1c levels. We investigated the relationship between achievement of American…”
Get full text

β-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes by Leiter, L. A.

“…Type 2 diabetes is caused by progressively increasing insulin resistance coupled with deteriorating β‐cell function, and there is a growing body of evidence to…”
Get full text

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials by Leiter, L. A., Betteridge, D. J., Farnier, M., Guyton, J. R., Lin, J., Shah, A., Johnson-Levonas, A. O., Brudi, P.

“…Aim: This post hoc analysis compared the lipid‐altering efficacy and safety of ezetimibe 10 mg plus statin (EZE/statin) vs. statin monotherapy in…”
Get full text

Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management by Aschner, P, Horton, E, Leiter, L A, Munro, N, Skyler, J S

“…The Diabetes Control and Complications Trial (DCCT) led to considerable improvements in the management of type 1 diabetes, with the wider adoption of intensive…”
Get more information

Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of Carbohydrates in Diabetes): a randomised controlled trial by Wolever, T. M. S, Mehling, C, Chiasson, J.-L, Josse, R. G, Leiter, L. A, Maheux, P, Rabasa-Lhoret, R, Rodger, N. W, Ryan, E. A

“…Aims/hypothesis We recently found that oral glucose tolerance over 1 year in type 2 diabetic patients declined to a significantly lesser degree on a…”
Get full text

Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study by Braga, M F B, Casanova, A, Teoh, H, Gerstein, H C, Fitchett, D H, Honos, G, McFarlane, P A, Ur, E, Yale, J-F, Langer, A, Goodman, S G, Leiter, L A

“…To prospectively evaluate diabetes management in the primary care setting and explore factors related to guideline-recommended triple target achievement [blood…”
Get more information